Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most promising future stocks according to Wall Street analysts. On August 14, analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT), retaining the price target of $137.00.

The analyst based the rating on Corcept Therapeutics Incorporated’s (NASDAQ:CORT) strategic plans and promising developments, stating that the company made notable progress with its novel glucocorticoid modulator, relacorilant.

The modulator saw improvements in both regulatory and clinical arenas. Nash added that the FDA has also accepted an NDA submission for relacorilant for the treatment of Cushing’s syndrome, and a decision is anticipated by the end of 2025.

The analyst also stated that Corcept Therapeutics Incorporated (NASDAQ:CORT) submitted another NDA for relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer, preparing for a potential launch by mid-2026.

Therefore, the potential of the expansion of relacorilant into oncology further supports the optimistic outlook for Corcept Therapeutics Incorporated (NASDAQ:CORT).

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions.

The company’s flagship product, Korlym, is FDA-approved for treating Cushing’s syndrome, a disorder caused by excessive cortisol production.

While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.